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Abstract
Canine lymphoma, as the most common haematopoietic malignancy, encompasses a
group of heterogeneous diseases and even within the T-cell immunophenotype, dif-
ferences in clinical presentation and responses to treatment exist. The aim of this ret-
rospective study was to determine outcomes and prognostic factors of 107 dogs
with multicentric non-indolent T-cell lymphoma (TCL) receiving lomustine-based
(70%) and non-lomustine-based (30%) treatment. The majority were Labradors,
Boxers, mixed-breed dogs and Dogue de Bordeaux. Eighty-six percent were substage
b, 77% had mediastinal involvement, 15% had suspected bone marrow involvement
and 12% had other extra-nodal sites of disease. The overall response rate to induc-
tion therapy was 80%; dogs receiving procarbazine in the induction protocol
(P = .042), dogs with neutrophil concentration below 8.7 × 10e9/L (P = .006) and
mitotic rate below 10 per 5 high power field (P = .013), had greater response rates.
Median progression-free survival (PFS) for the first remission was 105 days; lack of
expression of CD3 on flow cytometry (P < .0001) and pretreatment with steroid
(P = .012) were significantly associated with shorter PFS. Median overall survival time
(OST) was 136 days; co-expression of CD79a (P = .002), lack of CD3 expression on
flow cytometry, presence of anaemia (P = .007), and monocytopenia (P = .002) were
predictive of shorter OST. Multicentric non-indolent TCL in dogs is an aggressive
cancer with new possible prognostic factors.
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1 | INTRODUCTION
Lymphoma is the most common canine haematopoietic malignancy.1
Several negative prognostic factors have been identified, of which
T-cell immunophenotype is one of the most consistently reported.2-9
T-cell immunophenotype represents between 13% and 38% of cases
in the canine literature.3,8-13 Canine lymphoma classification can be
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based on clinical, morphological and immunological features. The
World Health Organization (WHO) classification of human Non-
Hodgkin Lymphoma has been extrapolated to canine lymphoma.13
Canine T-cell lymphoma (TCL) is a heterogeneous disease. It rep-
resents a wide spectrum of disease entities with varying responses to
treatment and prognoses. The two extremes are illustrated by the typ-
ically indolent T-zone lymphoma (TZL)14,15 and the aggressive hepato-
splenic lymphoma of gamma-delta T-cell lymphocytes.16 One study
found that the most common types of non-indolent TCLs were
peripheral TCL not otherwise specified (PTCLNOS—16%) and T-cell
lymphoblastic lymphoma (TLBL—5%).13 Other forms of non-indolent
TCL are extra-nodal, such as gastrointestinal lymphoma with modest
response to chemotherapy17 or cutaneous lymphoma with variable
clinical course.18 Currently, most studies on prognostic factors for
canine lymphoma examine a heterogeneous population of dogs with
different subtypes of lymphoma. Recently, it has been identified that
more defined subpopulations of lymphoma are characterized by dif-
ferent prognostic factors, as in the case of multicentric diffuse large
B-cell lymphoma.19,20 Currently, limited data on prognostic factors
specific for TCL as a separate clinical entity is available. Some of the
existing studies on canine TCL have included cases of indolent TZL or
anatomical presentations other than multicentric, which may be a sig-
nificant confounding factor for disease-free intervals and survival
times as well as for prognostic factors assessments. Brodsky et al,21
Rebhun et al22 and Brown et al23 did not find any statistically signifi-
cant prognostic factors in cohorts of dogs with different anatomical
forms of TCL treated with L-asparaginase/MOPP, CHOP and LOPP
chemotherapy protocol, respectively. Another study24 describing
70 dogs with non-indolent multicentric TCL treated with alkylating-
agent-rich combination protocol (VELCAP-SC) found that achieving
complete remission (CR) was statistically significant as an independent
predictor for progression-free survival (PFS) and overall survival time
(OST) and that substage b and Boxer breed were negative prognostic
factors. Morgan et al25 described the outcome in 35 dogs with non-
indolent TCL (including hepato-splenic and gastrointestinal forms)
treated with LOPP protocol. Multivariable analysis showed that Boxer
breed negatively impacted PFS and dogs with multicentric lymphoma
were more likely to achieve CR than other anatomical forms.
Multiple studies evaluating prognostic significance of haematologic
abnormalities in human and veterinary patients with lymphoma have
been published. Absolute lymphocyte concentration,26,27 monocyte
concentration (AMC),28 neutrophil:lymphocyte ratio (NLR),19,27,29,30 and
lymphocyte:monocyte ratio (LMR)19,31 have been the subjects of inves-
tigations. To the authors' knowledge, these have not yet been evalu-
ated in dogs with non-indolent TCL.
The purpose of this study was to describe patient demographics,
clinico-pathological abnormalities, and outcome of dogs with multi-
centric non-indolent TCL. We hypothesized that within the group of
non-indolent multicentric TCL treated with chemotherapy, treatment
type, haematologic parameters and flow cytometry characteristics
would be prognostic and that patient outcomes would be inferior to
previously reported studies.
2 | MATERIALS AND METHODS
2.1 | Study design and case collection
Record of dogs with non-indolent multicentric TCL that were referred
to three referral centres in the United Kingdom between January
2009 and June 2018 were retrospectively reviewed. Patients with
non-indolent lymphoma were included in the study if they had cyto-
logical or histologic diagnosis of lymphoma and T-cell
immunophenotype. Dogs were excluded if a definitive diagnosis was
not achieved, if immunophenotyping was not available, if cytological
or histopathological morphological characteristics were suggestive of
a “low grade” or TZL, or if neoplastic cells were lacking expression of
CD45. Dogs with non-multicentric forms such as gastrointestinal,
cutaneous and primary hepato-splenic lymphomas were excluded.
Clinical records were reviewed and follow-up data were obtained
from existing medical records and requested from referring veterinar-
ians by phone calls.
2.2 | Data collection
For each patient, the following data were recorded: signalment, body
weight, age at diagnosis, haematology results, calcium measurements,
clinical signs at presentation, method of diagnosis (cytology or histo-
pathology) and immunophenotyping.
Haematological abnormalities were defined based on the refer-
ence intervals provided by the laboratories concerned. Blood smear
reports (if available) were reviewed to assess for the presence of
circulating neoplastic cells, and to differentiate between true
thrombocytopenia and post-sampling platelet aggregation if auto-
mated low platelet count was reported. The abnormalities were
recorded prior to any treatment initiation. Median absolute leuko-
cyte concentrations were used to calculate the NLR and LMR
ratios. Patients were described as “hypercalcemic” when free
calcium levels or when total calcium levels were elevated without
concurrent hyperalbuminemia and clinical signs typically associated
with hypercalcemia of malignancy, such as polyuria/polydipsia were
present.
When available, blood smears and cytological slides of tissue and
fluid aspirates were reviewed by a single board-certified clinical
pathologist (L. M. P.). For the remaining cases, information was
obtained from the original cytopathology reports. Details recorded
included: nuclear size, nuclear shape, nucleoli (number, size, promi-
nence), cytoplasmic features, mitotic counts, presence of necrosis or
capillaries and prominence of tingible body macrophages. Mitotic rate
was defined as number of mitotic figures per five ×40 or ×50 high
power fields (hpf). Where sufficient information was available, lym-
phoma was tentatively classified based on the WHO classification
scheme, adapted to canine lymphoma,13 as well as previous publica-
tions on mediastinal TCLs in dogs.32 Cases were classified as lym-
phoma of granular lymphocytes (LGL) if they contained magenta
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cytoplasmic granules, typically located in one focal perinuclear area.
Lymphoma consisting of intermediate size nuclei (1.5-2 RBC in diame-
ter) with finely granular chromatin and inconspicuous nucleoli were
tentatively classified as lymphoblastic lymphomas (LBL). The remain-
der of the cases, having a large nucleus (>2 RBC) and/or prominent
nucleoli, were grouped together as TCLs not otherwise specified
(TCL-NOS).
The methods of immunophenotyping were recorded for each
case. For cases with flow cytometry available, receptor expression
patterns were recorded. Aberrant expression pattern on flow cyto-
metry was based by previously published criteria.33
Peripheral lymph node involvement was defined as enlargement
or firm consistency of peripheral lymph nodes on physical examination
or cytological/histological confirmation of lymphoma. Dogs presenting
with clinical signs associated with systemic illness were classified as
substage b. Full staging was performed at the attending clinician's dis-
cretion but was not required for inclusion.
Diagnostic imaging modalities and findings were recorded for
each case. If internal lymph nodes were enlarged, they were classified
as being involved. For liver and spleen, it was recorded whether the
involvement was confirmed with cytology or histology.
Where the information was available, presence of neoplastic lym-
phocytes in bone marrow aspiration or in peripheral blood smears was
used to classify cases as stage V according to WHO classification. All
dogs included in the study were classified according to WHO staging
criteria.
Treatment protocols, clinical response, date of progression, res-
cue treatments, date and cause of death and necropsy findings
(if available) were recorded for each patient. Similar to previous stud-
ies, dogs were classified as receiving steroids if there was any history
of continuous steroid administration for longer than 10 days prior to
commencing chemotherapy.19
Chemotherapy induction protocols were classified as 1-LOP
(lomustine- and vincristine-based, with/without L-asparaginase, procar-
bazine or cytarabine), 2-COP (vincristine- and cyclophosphamide-based,
with/without L-asparaginase or cytarabine), 3-CHOP or CEOP where
doxorubicin was replaced by epirubicin, with/without L-asparaginase or
cytarabine, 4-lomustine-based without vincristine (lomustine with/with-
out L-asparaginase or procarbazine) 5-prednisolone with/without L-
asparaginase only. Subsequently, chemotherapy induction protocols
were divided into lomustine-containing protocols vs others.
Response to first-line and rescue chemotherapy treatments was
based on the Veterinary Cooperative Oncology Group response eval-
uation criteria for peripheral nodal lymphoma34 and diagnostic imag-
ing findings for cases with internal involvement only. Cases were
classed as being in CR when lymph nodes (both peripheral or internal)
had returned to normal size; partial remission (PR) when lymph nodes
remained enlarged but had reduced in size by at least 30% and no
new lesions were recognized; progressive disease (PD) was used for
occurrence of new lesions or increase in size of enlarged lymph nodes
by at least 20%; and stable disease (SD) as a change in size of lymph
nodes which was not sufficient to be classified as PD or PR with no
occurrence of new lesions. In cases of solely internal involvement
where no imaging was available to directly measure the response, a
significant improvement in clinical signs was classified as
PR. Response had to be sustained for a minimum of 28 days to be
classified as a CR or PR. Dogs that died or were euthanized within
1 week of starting a treatment were considered as non-responders.
The objective response rate was defined as the sum of the cases with
a CR or a PR.
Rescue protocols were categorized as lomustine-based, doxorubicin-
based, COP (cyclophosphamide, vincristine, prednisolone)-type, DMAC
(dexamethasone, melphalan, Actinomycin D, cytarabine) or miscella-
neous. Number of rescue protocols and responses was recorded for each
patient.
PFS was defined as the period of time between treatment onset
and disease progression or death from any other cause. Dogs were
censored for PFS if lost to follow-up before progression occurred, if
still alive and in CR at the end of the follow-up period or if progression
did not occur before they died from cause other than lymphoma. OST
was defined as time between treatment onset and death from any
cause. Dogs were censored for OST if lost to follow-up, or still alive at
the end of the study period.
2.3 | Statistical analysis
Frequency and proportion were used to summarize categorical vari-
ables; median (minimum and maximum) was used for numerical
data. Fisher's exact test was used to compare sex/neutering status,
stage and substage of the dogs between institutions. Kruskal–
Wallis tests were used to compare body weight and age distribu-
tions between institutions. Kaplan-Meier curves were used to
depict survival curves and estimated median survival time reported.
Analytes with skewed results were divided into thirds (using tertile
cut-off points) prior to further analysis. Univariable and multivari-
able Cox regression were employed to evaluate predictors of PFS
and OST. Results were presented as hazard ratio (HR) and 95% con-
fidence intervals (CI). Two sets of univariable and multivariable
binary logistic regression were used to assess predictors of
responders (CR + PR) vs non-responders (SD + PD), and CR vs PR
of disease. Results were presented as odds ratio (OR) and 95%
CI. Results of univariable analysis are placed in a supplementary
material (Table S1). Variables that had P values <.1 in the
univariable analysis were included in the multivariable analysis.
Backward elimination method was used to obtain final multivariable
models. Because of missing data, several models were developed
with or without mitotic rate, CD3 or CD79a expression in the anal-
ysis. Significance level was set as 5%. Analyses were carried out in
R 3.5.1-R Core Team (2018).
2.4 | “Cell line validation statement”
Since no cell lines were used in the current study, validation testing
has not been conducted.
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3 | RESULTS
3.1 | Patient population
One hundred and seven dogs met the inclusion criteria. Forty-four
breeds were represented, the most common being Labrador retriever
(n = 19, 18%), Boxer (n = 14, 13%), crossbreed (n = 14, 13%), Dogue
de Bordeaux (n = 9, 8%), Cocker Spaniel (n = 8, 7%) and English
Springer Spaniel (n = 5, 5%).
The median body weight was 26.3 kg (range 4.6-87 kg) and the
median age was 6.5 years (range 1-14.8 years). There were 23 entire
males, 46 neutered males, 9 entire females and 29 spayed females.
There was no difference between the three institutions for sex,
neutering status (P value = .82), bodyweight (P = .11) and age (P = .09)
distribution of dogs.
Ninety-two dogs (n = 92, 86%) were classified as substage b. The
most common clinical signs at presentation were anorexia/hyporexia
(n = 63, 59%), lethargy (n = 60, 56%), polyuria/polydipsia (n = 39,
36%), vomiting and/or diarrhoea (n = 36, 34%) and respiratory signs
(n = 20, 19%).
3.2 | Diagnosis and cytology review
Eighty-five dogs (79%) were diagnosed based on cytological review of
tissue aspirates, 7 (7%) on histopathologic examination and 15 (14%)
had both. T-cell immunophenotype was determined by flow cyto-
metry in 57 dogs (53%), by demonstration of a clonal population of T
cells by polymerase chain reaction for antigen receptor rearrangement
(PARR) in 31 (29%), immunohistochemistry in 17 (16%) and immuno-
cytochemistry in 2 (2%). Among 57 dogs who had flow cytometry,
31 (54%) dogs had a non-aberrant immunophenotype and 26 (46%)
dogs had at least one aberrant expression pattern; among which
7 dogs had co-expression of CD4 and CD8, 9 dogs had loss of both
CD4 and CD8, 6 dogs had loss of CD3 expression and 7 dogs had
additional co-expression of B-cell markers (CD21 or CD79a).
Sixteen dogs (15%) were anaemic (Hct < 37%) and 29 (27%) were
thrombocytopenic (PLT <150 × 10e9/L) at initial diagnosis. Ten dogs
(9%) were neutropenic (neutrophil concentration < 3 × 10e9/L),
41 (38%) were lymphopenic (lymphocyte concentration < 1.3 × 10e9/L)
and 3 (3%) were monocytopenic (monocyte concentration <0.15 ×
10e9/L) at presentation. Calcium measurement was available for
106 cases. Fifty-seven dogs (53%) were shown to be hypercalcemic
prior to initiation of treatment.
From 100 dogs diagnosed on cytology, samples of 46 were avail-
able for review. For another 47 cases, detailed information could be
retrieved from the original reports. For remaining seven cases, only
limited reports with final diagnosis were available. Based on the cyto-
logical assessment, 73 cases were classified as TCL-NOS, 10 as LBL,
4 as LGL and 13 cases did not have enough information to be further
subclassified. In the seven cases that were diagnosed via histopathol-
ogy only, information on diagnosis was obtained from the original
reports.
3.3 | Staging
Results of staging are summarized in Table 1. According to WHO
staging system, 58 dogs (54%) were categorized as at least stage III,
18 (17%) as stage IV and 31 (29%) as stage V.
3.4 | Treatment and response rates
Two (2%) dogs were euthanized without any treatments and these
dogs were excluded from the PFS and OST analysis. Seven dogs (7%)
received prednisolone prior to commencing chemotherapy treatment.
One hundred and five dogs received chemotherapy induction proto-
cols as follows: 75 dogs (70%) received a lomustine-based chemother-
apy protocol including 73 (68%) LOP and 2 (2%) lomustine-based
protocols without vincristine. Eighteen dogs (17%) received COP
TABLE 1 Results of staging
Peripheral lymph node involvement 92 (86%)
Involvement of mediastinal and abdominal
lymph nodes only
15 (14%)
Diagnostic imaging of thorax and abdomen 83 (78%)
Thoracic Imaging using
Radiographs 43 (40%)
Computed tomography 35 (33%)
Ultrasound 5 (5%)
Documented mediastinal involvement 64/83 (77%)
Abdominal Imaging using
Ultrasound 44 (41%)
Computed tomography 36 (34%)
Radiographs 3 (3%)
Enlargement of abdominal lymph nodes 36/83 (43%)
Fine needle aspiration of the spleen
performed
38/83 (46%)
Splenic involvement confirmed on cytology 20/83 (24%)
Fine needle aspiration of the liver
performed
38/83 (46%)
Hepatic involvement confirmed on cytology 22/83 (27%)
Bone marrow involvement
Suspected 16 (15%)
Confirmed on bone marrow aspirate 7 (7%)
Extra-nodal involvement 13 (12%)
Kidney 5 suspected, 1
confirmed
Lung 4 suspected
Lytic lesion of the skull 1 suspected
Lytic lesion of the scapula 1 confirmed
Subcutaneous mass 1 confirmed
Urinary bladder 1 confirmed
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protocol, 7 dogs (7%) received CHOP or CEOP protocol and 5 dogs
(5%) received prednisolone with addition of L-asparaginase.
Among 105 dogs undergoing chemotherapy treatment, 59 dogs
(56%) achieved CR, 25 (24%) achieved PR, 7 (7%) had SD and 14 (13%)
experienced PD. The overall response rate (ORR, %CR and %PR) was
80%. For dogs receiving a lomustine-based chemotherapy protocol,
46 dogs (61%) achieved CR, 19 (25%) achieved PR with the ORR of 86%.
Univariable analysis of factors significantly associated with lack of
response to treatment and negative factors associated with PR vs CR
are presented in the supplementary file (Table S1).
Only nuclear shape (P = .017) and L/M ratio above 2.3 (P = .01)
remained statistically significant in the multivariable analysis (Table 2).
3.5 | First PFS and subsequent treatments
After induction treatment, median PFS was 105 days (range 1-1677).
Univariable analysis of the factors significantly associated with shorter
PFS is included in the supplementary file (Table S1). Since not all of
the lymphomas were investigated with flow cytometry, expression of
CD3 was recorded in 56/107 dogs (52%) only. Risk factors associated
with shorter PFS in the multivariable models of either including or
excluding CD3 expression are presented in Table 3.
Following relapse, 47 dogs (44%) received a rescue chemotherapy
treatment. Rescue chemotherapy included lomustine-based protocols
in 13 dogs (28%), doxorubicin-based protocols in 13 dogs (28%), COP
type protocol in 9 dogs (19%), DMAC in 5 dogs (10%) and other pro-
tocols in 7 dogs (15%).
Response to the first rescue treatment was recorded for 43/47
dogs. Overall response rate (CR and PR) to the first rescue treatment
was 57%. There were 10 CR (21%), 17 PR (36%), 7 SD (15%) and
9 PD (19%). Median PFS after the first rescue treatment was 53 days
(range 19-147). Twenty dogs (19%) received a second rescue chemo-
therapy protocol.
3.6 | Overall survival
Overall median survival time (MST) was 136 days (range 1-1677). Six
dogs were alive at the end of the study period, and one was lost to
follow-up. Seventy-five dogs had died or been euthanized because of
lymphoma and 23 dogs had been euthanized for another reason
including owner's preference with no clear indication of lymphoma
progression (7 dogs), chemotherapy-related complications (5 dogs),
pancreatitis (3 dogs), renal failure (2 dogs), sudden onset of lameness
(1 dog) or paraplegia (1 dog), half body radiation therapy-related com-
plications (1 dog), mammary carcinoma (1 dog), hemangiosarcoma
(1 dog) and ruptured splenic mass (1 dog).
Factors associated with shorter OST on univariable analysis are
presented in the supplementary file (Table S1). Multivariable analyses
of excluding either CD3 or CD79a or both factors were presented in
Table 4.
TABLE 2 Multivariable analysis of induction response
OR (95% CI)
P
value
Model 1 responders vs non-responders (n = 58)
Lack of procarbazine in the induction
protocol
8.5 (1.3, 91.6) .0419
Neutrophil concentration > 8.7 12.1 (2.3, 89.1) .0062
Mitotic rate 5–10 vs < 5 2.0 (0.2, 22.7) .5305
Mitotic rate > 10 vs < 5 15.1 (2.1, 173.4) .0130
Model 2 responders vs non-responders (excluding mitotic rate;
n = 104)
Neutered vs entire 0.2 (0.1, 0.8) .0195
Lack of procarbazine in the induction
protocol
11.2 (2.8, 64.2) .0021
Neutrophil concentration > 8.7
vs < 5.4
9.8 (2.5, 47.0) .0020
Model 3 complete remission vs partial remission (n = 70)
Nuclear complexity: cleaved complex
vs round mildly indented
5.3 (1.4, 23.4) .0171
L/M ratio > 2.3 vs < 1 8.9 (1.9, 57.1) .0099
TABLE 3 Multivariable analysis of progression free survival
HR (95% CI) P value
Model 1 including CD3 (n = 56)
Lack of CD3 expression 8.7 (3.1, 24.8) <.0001
Steroids prior to diagnosis/treatment 5.3 (1.4, 19.4) .0123
Model 2 excluding CD3 (n = 104)
Presence of monocytopenia 9.6 (2.7, 33.8) .0004
Steroids prior to diagnosis/treatment 3.3 (1.4, 8.2) .0088
Neutrophil concentration > 8.7
vs < 5.4
2.2 (1.2, 3.9) .0087
TABLE 4 Multivariable analysis of overall survival
HR (95% CI) P value
Model 1 excluding both CD3 and CD79a (n = 89)
Nuclear complexity: cleaved complex
vs round mildly indented
1.7 (1.1, 2.7) .0244
Presence of anaemia 2.8 (1.5, 5.2) .0009
Neutrophil concentration > 8.7
vs < 5.4
2.9 (1.5, 6.1) .0027
Model 2 including CD79a (n = 48)
Presence of CD79a expression 5.4 (1.9, 15.1) .0015
Presence of anaemia 3.7 (1.4, 9.6) .0067
Presence of monocytopenia 23.0 (2.9, 177.5) .0026
Model 3 including CD3 (n = 56)
Lack of CD3 expression 4.2 (1.6, 10.9) .0033
Presence of anaemia 2.5 (1.1, 5.7) .0291
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4 | DISCUSSION
In this study, we describe the clinical and pathological findings from a
homogenous population of dogs with non-indolent multicentric TCL.
We found that the median PFS and OS of the whole group were
lower than previously reported for dogs with TCL,21-25 which suggests
that prognosis for this lymphoma subtype is worse than described for
TCL in general. However, a selection bias in the present study owing
to case recruitment solely from specialist referral centres cannot be
rule out, and could explain why our study population contained a large
proportion of patients in clinical stage IV and V, with a majority in sub-
stage b (86%).
Stage and substage have been previously reported as prognostic
in canine lymphoma35,36,57 but we were unable to confirm this in our
study. Results from previous studies may have been confounded by a
variability of heterogeneous lymphoma subtypes included but it is also
possible that the number of dogs with certain factors was too low in
our study to show a statistical significance.
Not surprisingly, one of the breeds most commonly represented
in our study was the Boxer. Several studies showed increased preva-
lence of TCL in this breed.21,22,37,38 In a recent study by Morgan
et al,25 the PFS was shorter in the Boxer breed, this association was
not seen in our study, possibly because of low numbers of Boxers
included. More interestingly, Dogue de Bordeaux's predisposition to
TCL has been previously reported among canine population in
Poland,38 and more recently in Australian population,39 however,
these studies did not exclude indolent forms of lymphoma. Dogue de
Bordeaux was the fourth most commonly represented breed in our
study, which might further support a possibility of this breed being
truly predisposed.
A large proportion (77%) of dogs in our population had evidence
of mediastinal involvement on imaging, which is the highest reported
to date. Since not all dogs (83/107) underwent thoracic imaging, this
number may be even higher. Starrak et al40 reported that 64.4% of
270 dogs with lymphoma had evidence of mediastinal lymphadenopa-
thy on thoracic radiographs. Its presence was negatively associated
with PFS and OST but this likely represents the association with T-cell
immunophenotype as an independent prognostic factor. Study evalu-
ating prognostic factors in lymphoma with associated hypercalcemia41
showed that presence of a mediastinal mass negatively impacted PFS.
Mediastinal involvement did not influence any of the outcomes in our
study, similarly to others.22
The response to induction chemotherapy treatment was high
(80% for all chemotherapy protocols and 86% for lomustine-based
protocols). This rate was similar in some studies21-23,25 and lower in
others.24 Multivariable analysis showed that inclusion of procarbazine
in the induction protocol was associated with higher likelihood of
response to chemotherapy. Increased expression of one of the drug
transporters of the ATP-Binding Cassette superfamily, BCRP
(ABCG2), was shown in canine TCL.42 As a main mechanism of lym-
phoma resistance to anthracyclines, this might explain low response
rates to doxorubicin in dogs with TCL.43 Lomustine and procarbazine,
as alkylating agents, are not typical substrates for the ABC
transporters, which might explain their potential benefit. Although
there was a benefit in PFS and OST for dogs receiving lomustine-
based induction chemotherapy in our study, this difference was not
statistically significant comparing to other types of treatment.
In the multivariable analysis, lack of expression of CD3 was asso-
ciated with a shorter PFS. Deravi et al44 described absence or low
CD3 expression in 38/101 (38%) of dogs with multicentric TCL. How-
ever, in their study it had no statistical significance for PFS or OST.
The co-expression of CD79a was associated with shorter OST in our
study. Although co-expression of B-cell markers in canine TCL has
been previously reported,14,45 its prognostic significance in other
studies remains uncertain. Interestingly, 5/6 dogs that lacked CD3
expression on flow cytometry were classified as TCL-NOS on cytol-
ogy; further work is needed to investigate a possible association of
different aberrant immunophenotypes with lymphoma subtypes. Mor-
phological subtype alone can influence the outcome in dogs with TCL,
such as dogs with lymphoblastic subtype identified by Valli13 as hav-
ing shorter survival. Since not all of the cytological samples were avail-
able for review, there is a possibility that an association between
particular lymphoma subtypes and the outcome was not detected in
this study.
Steroid administration prior to treatment with chemotherapy was
associated with shorter PFS in the multivariable analysis, similarly to
previous studies.46-48 The suspected mechanism of its negative
impact has been correlated with induction of multidrug resistance.
On multivariable analysis, the presence of anaemia remained sta-
tistically significant for shorter survival. Although this is in accordance
with previous studies,19,49,50 the mechanism explaining its prognostic
value remains unclear. Anaemia of chronic/inflammatory disease or
bone marrow infiltration was most commonly suspected.
In the multivariable analysis, different factors were significantly
associated with risk of not responding to the induction treatment or
with shorter survival, such as neutrophil concentration above
8.7 × 10e9/L and LMR above 2.3, mitotic rate above 10 per 5 hpf and
nuclear shape. Absolute leukocyte concentrations and their ratios
should be interpreted with caution in canine patients since they can
be influenced by different aspects of systemic inflammation but can
also be induced by stress. This is reflected in conflicting results found
in two separate studies on canine lymphoma.19,27 Mitotic index has
been shown as an independent prognostic factor in various malignant
tumours in dogs.51,52 However, it should be noted that in our study,
mitotic index was evaluated on cytology not histopathology samples
and this variable was not available for review in all of the dogs
included. Nuclear complexity is typically associated with the T-cell
immunophenotype. Its prognostic value within this subgroup is more
difficult to explain. Studies including cytological review, ideally mat-
ched with histopathological samples would be required to further
investigate this variable.
Presence of monocytopenia was significantly associated with
shorter PFS and OST in the multivariable analysis. Although AMC was
shown to hold a prognostic value in previous studies,53,54 only three
dogs in our study population had monocytopenia in the pre-treatment
haematology, hence this should be interpreted with caution.
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This study has limitations, such as its retrospective nature. Inclu-
sion criteria aimed to identify a homogenous population of multi-
centric TCL in dogs, however in one third of the study population,
T-cell immunophenotype was determined only by demonstration of a
clonal population of T cells by PARR. PARR is not a preferred tool for
immunophenotyping as cross-lineage rearrangement has been
reported.55 Flow cytometry was shown superior over PARR for
immunophenotyping,56 however in the absence of fresh samples,
PARR can be an acceptable alternative, especially in conjunction
with clinical signs typical of TCL, such as hypercalcemia. Although
this study aimed to evaluate a specific subtype of canine lymphoma,
because of its retrospective nature, not all dogs were uniformly
staged and the level of treatment received by dogs varied. Response
to treatment in dogs without peripheral lymphadenomegaly was
assessed mainly based on clinical signs, rather than imaging studies,
which would allow a more reliable, measurable response. Despite its
relatively large population size, not all of the variables were
recorded for each individual. This might undermine the significance
of the discovered potential prognostic factors. On the other hand,
statistical evaluation of a large number of variables creates the pos-
sibility of generating false positive associations by chance. Larger
prospective multicentric studies are necessary to characterize non-
indolent multicentric TCL in dogs in order to explore the most effec-
tive treatment, as it will become a stronger model for the human
counterpart.
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